| abstract |
The present disclosure relates to functionalized amino compounds that can provide inhibitors of C-reactive protein (CRP). The present disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of CRP associated diseases, disorders or conditions, and particularly the treatment of inflammation associated with pro-inflammatory effects of CRP, and to related uses. |